Mps1 is SUMO-modified during the cell cycle

Agnese Restuccia; Feikun Yang; Changyan Chen; Lou Lu; Wei Dai

doi:10.18632/oncotarget.6552

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Mps1 is SUMO-modified during the cell cycle

Agnese Restuccia, Feikun Yang, Changyan Chen, Lou Lu and Wei Dai _

PDF | HTML | How to cite

Oncotarget. 2016; 7:3158-3170. https://doi.org/10.18632/oncotarget.6552

Metrics: PDF 2251 views | HTML 2775 views | ?

Abstract

Agnese Restuccia1,*, Feikun Yang2,*, Changyan Chen3, Lou Lu4, Wei Dai2

1Division of Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany

2Departments of Environmental Medicine, Biochemistry and Molecular Pharmacology, New York University Langone Medical Center, Tuxedo Park, NY, USA

3Center for Drug Discovery, Northeastern University, Boston, MA, USA

4Division of Molecular Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Torrance, CA, USA

*These authors contributed equally to this work

Correspondence to:

Wei Dai, e-mail: [email protected]

Keywords: Mps1, mitosis, sumoylation, BubR1

Received: August 24, 2015 Accepted: November 21, 2015 Published: December 10, 2015

ABSTRACT

Mps1 is a dual specificity protein kinase that regulates the spindle assembly checkpoint and mediates proper microtubule attachment to chromosomes during mitosis. However, the molecular mechanism that controls Mps1 protein level and its activity during the cell cycle remains unclear. Given that sumoylation plays an important role in mitotic progression, we investigated whether Mps1 was SUMO-modified and whether sumoylation affects its activity in mitosis. Our results showed that Mps1 was sumoylated in both asynchronized and mitotic cell populations. Mps1 was modified by both SUMO-1 and SUMO-2. Our further studies revealed that lysine residues including K71, K287, K367 and K471 were essential for Mps1 sumoylation. Sumoylation appeared to play a role in mediating kinetochore localization of Mps1, thus affecting normal mitotic progression. Furthermore, SUMO-resistant mutants of Mps1 interacted with BubR1 more efficiently than it did with the wild-type control. Combined, our results indicate that Mps1 is SUMO-modified that plays an essential role in regulating Mps1 functions during mitosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6552

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Mps1 is SUMO-modified during the cell cycle

Abstract